BioCentury
ARTICLE | Clinical News

Capricor stem cell therapy misses heart repair endpoint

May 12, 2017 8:57 PM UTC

Capricor Therapeutics Inc. (NASDAQ:CAPR) sank $1.89 (62%) to $1.16 in afternoon trading on Friday after it said a six-month interim futility analysis showed intracoronary CAP-1002 is unlikely to meet the primary endpoint compared to placebo in the Phase II trial ALLSTAR evaluating the stem cell therapy's effect on heart repair after a heart attack. The primary endpoint is the percent change from baseline to 12 months in scar size as a percentage of left ventricular mass, measured by MRI, among 142 patients with residual cardiac dysfunction following a large heart attack.

The company plans to cut staff and focus primarily on developing CAP-1002 to treat Duchenne muscular dystrophy (DMD). Next half, it plans to begin a randomized, placebo-controlled study that will evaluate the effects of IV CAP-1002 on skeletal muscle function...

BCIQ Company Profiles

Capricor Therapeutics Inc.